SEHK:2162Biotechs
Keymed Biosciences (SEHK:2162) Hits A Phase III Milestone, Is The Upside Already Priced In?
Keymed Biosciences (SEHK:2162) is back in focus after announcing that CMG901, its CLDN18.2-targeting antibody drug conjugate co developed with AstraZeneca, met primary and key secondary overall survival endpoints in a global Phase III gastric cancer trial.
See our latest analysis for Keymed Biosciences.
The positive CMG901 news arrives after a strong run in Keymed Biosciences, with the share price at HK$81.85 and a year to date share price return of 53.13%, while the 3 year total shareholder...